Phase II Trial of Sorafenib in Advanced Thyroid Cancer

2008676 citationsJournal Articlegreen Open Access

Authors

Vandana G. Abramson · Abramson Cancer Center

Andrea B. Troxel · Abramson Cancer Center

Anoma Nellore · University of Pennsylvania

Kanchan Puttaswamy · Abramson Cancer Center

Maryann Redlinger · Abramson Cancer Center

K. Ransone · Abramson Cancer Center

Susan J. Mandel ·

Abstract

Sorafenib has clinically relevant antitumor activity in patients with metastatic, iodine-refractory thyroid carcinoma, with an overall clinical benefit rate (partial response + stable disease) of 77%, median PFS of 79 weeks, and an overall acceptable safety profile. These results represent a significant advance over chemotherapy in both response rate and PFS and support further investigation of this agent in these patients.

Topics & Keywords

Thyroid Cancer Diagnosis and Treatment Cancer-related Molecular Pathways Cancer Mechanisms and Therapy

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: Journal of Clinical Oncology

Volume 26, Issue 29, pp. 4714-4719

DOI: 10.1200/jco.2008.16.3279

Field-Weighted Citation Impact: 38.54